Live tape
Top 8, mentions 7d15,265NVDA6,540 mentions▲ +0.04GOOGL1,864 mentions▲ +0.04SPY1,671 mentions▲ +0.05QQQ1,446 mentions▲ +0.05SPCX1,139 mentions▲ +0.06AMD950 mentions▲ +0.08MSFT842 mentions▲ +0.03CRWV813 mentions▲ +0.07

Equity · Healthcare

BCAX

NASDAQ

Bicara Therapeutics (BCAX)

10.18 USD +1.90% vs prior close Nov 10, 2026
Bicara Therapeutics Inc. price graph
63 sessions
30 0 13 Aug 10 Nov

The line runs 24 USD on 13 August through 10.18 USD on 10 November, on a scale from 0 to 30. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
675.8M USD
EPS, diluted, year to Dec 2025
−2.52 USD
52-week range
7.92 USD – 30 USD
Avg volume
119.2K

as of Nov 10, 2026

Have Bicara Therapeutics (BCAX) insiders bought or sold shares recently?

In the 90 days to 11 Nov 2026, Bicara Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); none has bought on the open market since 26 Feb 2026.

Form 4, 90 days to 11 Nov 2026, newest reported trade 8 Sep 2026

0buys
1sells
$401Knet sold
1other filings
Have Bicara Therapeutics (BCAX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
08 Sep 2026Cohlhepp RyanPresident, COO & Interim CEOSell17,500401K USD
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Bicara Therapeutics (BCAX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
08 Sep 2026Cohlhepp RyanPresident, COO & Interim CEOOption exercise17,50066K USD

Which funds hold Bicara Therapeutics (BCAX)?

5 of the 45 institutional funds we track reported a Bicara Therapeutics position for the quarter ended 30 Jun 2026 — a combined 31.1M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Bicara Therapeutics (BCAX)?
FundPositionSharesValueShares q/q
D. E. Shaw & Co.Added498,19314.8M USD+79.9%
Millennium ManagementAdded262,2547.8M USD+67.4%
Citadel AdvisorsTrimmed211,1426.3M USD−87.3%
Two Sigma InvestmentsTrimmed46,6061.4M USD−48.1%
AQR Capital ManagementAdded29,917888K USD+126.9%
Balyasny Asset ManagementExited

What has been filed or recorded for Bicara Therapeutics (BCAX)?

The filings we hold for Bicara Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Bicara Therapeutics (BCAX)?
And
14 Oct 2026Fails to deliverShares failed to deliver267 shares5K USD notional · <0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver2,298 shares40K USD notional · 0.003% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −1.04 USD
30 Sep 2026FinancialsTotal assets460.6M USDat period end
30 Sep 2026FinancialsTotal equity409.4M USDat period end
28 Sep 2026Fails to deliverShares failed to deliver326 shares6K USD notional · <0.001% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.82 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.93 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −2.52 USD
31 Dec 2025FinancialsNet income−138.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.52 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.67 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.50 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.68 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −4.05 USD

What do people ask about Bicara Therapeutics (BCAX)?

From live data
What did Bicara Therapeutics shares close at?10.18

Bicara Therapeutics closed at 10.18 USD on 10 Nov 2026, up 1.90% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Bicara Therapeutics’ market cap?675.8M

Bicara Therapeutics is worth 675.8M USD by market value as of 10 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Bicara Therapeutics insiders bought or sold shares recently?1 sale

In the 90 days to 11 Nov 2026, Bicara Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); none has bought on the open market since 26 Feb 2026. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Bicara Therapeutics?5 of 45

5 of the 45 funds we track reported a Bicara Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Millennium Management and Citadel Advisors. See Funds

When did Bicara Therapeutics last report earnings?−1.04

Bicara Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.04 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings